An Open-label, Randomised, Single Dose, Cross-over Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711
Latest Information Update: 13 Jul 2020
At a glance
- Drugs Rezivertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Beta Pharma
Most Recent Events
- 07 Jul 2020 Status changed from active, no longer recruiting to completed.
- 25 Mar 2020 Planned primary completion date changed from 1 May 2020 to 1 Apr 2020.
- 25 Mar 2020 Status changed from not yet recruiting to active, no longer recruiting.